Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial

Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial

<p>Background</p> <p>Nepalese infants receive ten-valent pneumococcal conjugate vaccine (PCV10) with a 1 month interval between priming doses for programmatic reasons. We aimed to investigate whether immune responses to PCV10 serotypes were non-inferior if the second priming dose o...

Full description

Bibliographic Details
Main Authors:	Kandasamy, R, Gurung, M, Thorson, S, Yu, LM, Galal, U, Voysey, M, Kelly, S, Wahl, B, Berbers, G, Finnegan, K, Ansari, I, Paudel, K, Murdoch, DR, O'Brien, KL, Kelly, DF, Goldblatt, D, Shrestha, S, Pollard, AJ
Format:	Journal article
Language:	English
Published:	Elsevier 2019

Similar Items

Persistence of immunity following 2-dose priming with a 10-valent pneumococcal conjugate vaccine at 6 and 10 weeks or 6 and 14 weeks of age in Nepalese toddlers
by: Gurung, M, et al.
Published: (2021)

Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: a pre-post comparison study
by: Kandasamy, R, et al.
Published: (2024)

Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.
by: Hamaluba, M, et al.
Published: (2015)

Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study
by: Shrestha, S, et al.
Published: (2022)

Multi-serotype pneumococcal nasopharyngeal carriage prevalence in vaccine naive Nepalese children, assessed using molecular serotyping.
by: Kandasamy, R, et al.
Published: (2015)

Evaluation of acute and convalescent antibody concentration against pneumococcal capsular polysaccharides for the diagnosis of pneumococcal infection in children with community-acquired pneumonia
by: Carter, MJ, et al.
Published: (2024)

Multi-serotype pneumococcal nasopharyngeal carriage prevalence in vaccine naïve Nepalese children, assessed using molecular serotyping.
by: Rama Kandasamy, et al.
Published: (2015-01-01)

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
by: Trück, J, et al.
Published: (2016)

Assessment of an antibody-in-lymphocyte supernatant assay for the etiological diagnosis of pneumococcal pneumonia in children
by: Carter, MJ, et al.
Published: (2020)

Differences in immunization site pain in toddlers vaccinated with either the 10- or the 13-valent pneumococcal conjugate vaccine
by: Trück, J, et al.
Published: (2018)

Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries
by: Voysey, M, et al.
Published: (2017)

Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom
by: Kandasamy, R, et al.
Published: (2019)

Effect of childhood vaccination and antibiotic use on pneumococcal populations and genome-wide associations with disease among children in Nepal: an observational study
by: Kandasamy, R, et al.
Published: (2022)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
by: Paul Turner, et al.
Published: (2015-11-01)

Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data
by: Feng, S, et al.
Published: (2023)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

Clinical profile of invasive pneumococcal diseases in Patan Hospital, Nepal.
by: Chhetri, U, et al.
Published: (2011)

Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil
by: Indianara Maria Grando, et al.
Published: (2015-02-01)

Assessment of an Antibody-in-Lymphocyte Supernatant Assay for the Etiological Diagnosis of Pneumococcal Pneumonia in Children
by: Michael J. Carter, et al.
Published: (2020-01-01)

Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study
by: Shrijana Shrestha, ProfMD, et al.
Published: (2022-10-01)

A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine.
by: Hamaluba, M, et al.
Published: (2015)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
by: Irina Kislaya, et al.
Published: (2019-01-01)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01)

High-throughput bacterial SNP typing identifies distinct clusters of SalmonellaTyphi causing typhoid in Nepalese children
by: Holt, K, et al.
Published: (2010)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.
by: Sweta M Patel, et al.
Published: (2022-01-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
by: Sweta M. Patel, et al.
Published: (2022-01-01)

Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant dataResearch in context
by: Shuo Feng, et al.
Published: (2023-07-01)

Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age
by: Bijukchhe, SM, et al.
Published: (2024)

Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany
by: Min Huang, et al.
Published: (2024-09-01)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: Anna M.M. van Deursen, et al.
Published: (2012-11-01)

Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
by: Alienke J Wijmenga-Monsuur, et al.
Published: (2015-01-01)

Nasopharyngeal carriage of pneumococcus in children in England up to 10 years after 13-valent pneumococcal conjugate vaccine introduction: persistence of serotypes 3 and 19A and emergence of 7C
by: Tiley, KS, et al.
Published: (2022)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017-03-01)

Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
by: Els van Westen, et al.
Published: (2018-12-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Correction: Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
by: Alienke J Wijmenga-Monsuur, et al.
Published: (2016-01-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Adamu, AL, et al.
Published: (2023)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Aishatu L. Adamu, et al.
Published: (2023-05-01)

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
by: Mitchell, R, et al.
Published: (2013)